Teonanacatl

Depressive Disorder

Yale UniversitySmall moleculePhase 2Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 73/ 100

Competitive context

77 Active assets in the Depressive Disorder cohort.

Asset / Sponsor	Phase	Rating
Brexpiprazole Dr. Albert Kar-Kin Chung	Phase 4	A
Saredutant Sanofi	Phase 3	BBB
Jnj-54135419 Chinese PLA General Hospital	Phase 4	BBB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone VA Office of Research and Development	Phase 4	BBB
Fluoxetine University of Oxford	Phase 4	BBB

View all 50 →

Same molecule, other indications

Teonanacatl is also rated in:

hematopoietic and lymphoid system neoplasmActive

BB

Indicative · Phase 2

65 / 100

major depressive disorderActive

BB

Indicative · Phase 3

65 / 100

bipolar II disorderActive

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.